Business Context and Reporting Period
This Form 6-K filing by Fresenius Medical Care AG & Co. KGaA covers the month of June 2013, with the report dated June 27, 2013. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the period. The primary financial disclosure relates to capital allocation:
- Share Buy-Back Program: The company is executing a program announced on April 4, 2013, with a total value of €385 million (approximately $500 million).
- Program Status: Repurchases commenced on May 20, 2013, and are expected to conclude in the third quarter of 2013.
Material Changes
The filing details the ongoing execution of the share repurchase program. No other material changes to operations or financial position are disclosed in this specific document.
Guidance, Outlook, and Management Commentary
Management indicates that the share buy-back program is expected to reach fruition in the third quarter of 2013. The company commits to posting the number of shares acquired and their corresponding cost on its website every Monday for purchases made in the preceding week. Additionally, repurchase data will be included in quarterly 6-K submissions starting with the report for the quarter ending June 30, 2013.
Investor Verification Checklist
- Verify the weekly share repurchase data posted on the company website (http://www.fmc-ag.com/4884.htm).
- Monitor the upcoming quarterly 6-K filing for the quarter ending June 30, 2013, for detailed repurchase tables.
- Confirm the completion of the €385 million buy-back program in the third quarter of 2013.